In recent earnings, Recursion shared more details about our RBM39/REC-1245 program. In the video below, I share how the Recursion platform accelerated our RBM39 program and uncovered novel biology along the way.
Check it out to learn more!
💡 Explain the Impact: Using data & AI to deliver a new cancer drug to clinic twice as fast as industry average
Chase Neumann, PhD (@OncNTechStuff), Associate Director of Oncology, shares how we used the Recursion OS to discover new ways to target aggressive cancers and identify biomarkers that can better guide patient selection and improve outcomes.
Chase explains how the platform led to a key discovery: that removing a protein called RBM39 mimicked the effect of targeting the desirable cancer regulator, CDK12, without the undesired toxic side effects. And how that same AI platform helped us to quickly and efficiently precision-design a molecule, REC-1245, and determine, via causal modeling, the patient population who would be most likely to benefit.
💥 It’s precision oncology in action.
*Link to blog below to learn more!
Genuine concern about this take.
What happens when the non scientific community hears curing diseases in 10 years? From my perspective, we build a bigger gap in the public's trust of science if we cannot deliver on these promises.
@UrnovFyodor - thoughts?
@UrnovFyodor Agreed it will positively impact. I have been working in the space for awhile. The AI impact is already tangible.
My concern is the public side: making a positive impact on disease outcomes vs cure. Reminds me a lot of the cure cancer campaigns that have propagated over time.
Genuine concern about this take.
What happens when the non scientific community hears curing diseases in 10 years? From my perspective, we build a bigger gap in the public's trust of science if we cannot deliver on these promises.
@UrnovFyodor - thoughts?
Completely agree with @MelindaBChu1!
I hope investors don't fall for this as the primary deliverable for the valuation. If that's what success looks like, @AnthropicAI will struggle to deliver on these extreme goals.
Disclosure - I believe in AI for Bio, but this is unlikely.
🚨There is 0% this is possible. If you are developing drugs 🔺dementia or diseases with long-term follow-up, 🔺
🚨You can’t have a 12-week study and say you cured dementia. A participant has to be followed at least 12 months to 24 months.
Your trial at Phase 2 and 3 is going to be a minimum of 24 months; will say Phase 1 12 months (that’s 5 years in trials)
Fastest 6, 7-8 years with some kind of breakthrough designation. No one’s fault that’s the biology.
==
Ok, let’s say discovery and even synthesis of a compound takes 1 day (takes weeks to months) I’ll even say animal studies and IND take 12 months. So with human trials even if everything goes perfectly.
🚨 So it’s 6 or 7-8 years to approval even with some kind of breakthrough designation.
Also, they have zero drug candidates. A normal
thing to say after this is “we’re seeing progress in the lab”, but they don’t have anything.
It’s not being negative. It’s just not possible to assess a long-term outcome in a short time frame.
🚨There is 0% this is possible. If you are developing drugs 🔺dementia or diseases with long-term follow-up, 🔺
🚨You can’t have a 12-week study and say you cured dementia. A participant has to be followed at least 12 months to 24 months.
Your trial at Phase 2 and 3 is going to be a minimum of 24 months; will say Phase 1 12 months (that’s 5 years in trials)
Fastest 6, 7-8 years with some kind of breakthrough designation. No one’s fault that’s the biology.
==
Ok, let’s say discovery and even synthesis of a compound takes 1 day (takes weeks to months) I’ll even say animal studies and IND take 12 months. So with human trials even if everything goes perfectly.
🚨 So it’s 6 or 7-8 years to approval even with some kind of breakthrough designation.
Also, they have zero drug candidates. A normal
thing to say after this is “we’re seeing progress in the lab”, but they don’t have anything.
It’s not being negative. It’s just not possible to assess a long-term outcome in a short time frame.
Congrats to @AnthonyrSloan on leading this transformative effort! I think this opens up many avenues for future projects. For anyone hiring, this man is on the job market and will make an exceptional independent investigator.
I'm very happy to share the final version of our paper, “MCT1-dependent mitochondrial lactate import sustains cardiac metabolism,” out in Nature! We show how lactate fuels heart mitochondria and helps protect the heart during stress. https://t.co/QRztJAzfW7 @UofUBiochem 1/10
Today we can finally talk about @enveda's partnership with @AnthropicAI . “Partnership” is a word that covers a lot of sins, so here is what it actually bought us:
1. a Phase 2 program pulled forward by three weeks
2. an IND submission accelerated for another soon-to-be-announced clinical program
3. an Investigator’s Brochure, drafted by @claudeai and signed off by our team after one minor edit, now in front of the FDA
We chose to work with Anthropic on development, not discovery. Enveda already finds medicines faster than we can develop them, and I think the industry is heading the same way. The slowest part of development is paperwork, directly or indirectly: batch records, study reports, the Investigator’s Brochure, and the IND that packages it all for the FDA. Discovery gets the headlines. Document review is where the months go.
Test 1: manufacturing batch release for a Phase 2 program. Before a batch can go to a trial, someone checks every page of its manufacturing record by hand. Claude read 1,061 scanned, largely handwritten pages from the campaign. Four of our reviewers and outside consultants independently reviewed the same pages, and a Quality adjudicator scored every comment against one question: would an FDA auditor raise it? Claude matched all 11 actionable issues the experts found and added 7 they had missed. Review time fell from 26 hours (typically spread over several weeks) to under 3, an 89% reduction, for about $37 in model cost. On another program, it flagged a climbing impurity that routine review had cleared; it later went out of specification.
Test 2: the Investigator’s Brochure for an IND, drafted in four hours instead of weeks. For a new Enveda medicine about to enter human trials, Claude drafted the brochure every trial physician relies on, from a structured layer of facts pulled from our tox, bioanalytical, and PK reports. Our reviewers found one minor unit-conversion error. We fixed it and included that draft in the IND. From the same source layer, Claude drafted the core of the IND itself in four hours, work that takes the best teams a month or more.
None of this works unless the model stays factful, so we built a custom harness to force it. It reads every page as an image, keeps a code ledger of which pages it read, and ties every finding to its page and governing document. Across the evaluation, no finding cited anything that was not in the record.
The full method is public. Our technical report on the CMC Document Processor covers the architecture, GMP controls, study design, and results, and we open-sourced a companion implementation so you can build your own!
Thank you to the incredible @enveda and @AnthropicAI teams for making this possible.
@allmeasures Couldn't agree more. What about cell lineage as a determinant? Hypoxia and many other stimuli look dramatically different depending on origin.
Great work @Recursion! Exciting to see the progress for REC-1245 (huge fan) and to see 3 PRs in the dose escalation is so exciting! So proud to have been a small part of it! 🎉🔥
Recursion Announces New Clinical Data Across Two Potential First-in-Class Programs, Sanofi Partnership Milestone, and Oversubscribed $200M Offering
Today, we announced important progress across our clinical pipeline, partnerships, and capital position—reflecting growing evidence of what our integrated AI-enabled drug discovery platform can deliver.
🚀 REC-4881 | Deep, durable polyp reductions in FAP
In an expanded adult population (18+), 87% of patients achieved polyp burden reductions after 12 weeks (47% median), with 85% remaining below baseline after 12 weeks off treatment.
In the upper GI—the area of greatest unmet need—92% achieved reductions (55% median), including two patients with near-complete reductions (≥98%). Of those with reductions, 92% remained below baseline after 12 weeks off treatment.
With no approved pharmacologic therapies for FAP, we are targeting registrational trial initiation in 2H 2027, pending FDA discussions. Full data will be presented November 2 at CGA-IGC.
🚀 REC-1245 | Encouraging early activity in heavily pretreated cancer patients
Our potential first-in-class oral RBM39 degrader demonstrated three partial responses (two confirmed in endometrial cancer; one unconfirmed in liver cancer) and 91.7% disease control (11/12) at doses ≥45 mg. No dose-limiting toxicities or treatment-related serious adverse events were observed at the selected 45 mg expansion dose.
🚀 Sanofi | First development candidate optioned
Two challenging targets, one oral molecule. A potential first-in-class candidate for inflammatory disease, enabled by Recursion’s AI platform and small-molecule chemistry capabilities alongside Sanofi’s expertise.
Phase 1 expected in 2027, marking the sixth progress-based milestone across our collaboration.
🚀 $200M Oversubscribed Follow-On Offering | Extending Runway Into 2029
Broad demand from leading healthcare specialists, long-only institutions, and growth investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, and Driehaus Capital Management.
The financing supports advancement of our clinical pipeline, continued AI engine innovation, and strategic partnerships.
Multiple independent proof points. Across diseases, programs, and partnerships. Powered by one integrated AI-enabled engine.
Thank you to our employees, collaborators, clinical investigators, patients, and investors who make this progress possible.
Links below 👇
Business Update: https://t.co/mauWHLYph4
Sanofi announcement: https://t.co/NXtdrzWiGr
Public offering: https://t.co/nUr3XMg7Zg